NCT06669533View on ClinicalTrials.gov

Use Misoprostol to Optimize Prevention of Cervical Cancer

NARecruitingINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

February 25, 2025

Primary Completion Date

November 4, 2026

Study Completion Date

November 4, 2027

Conditions
Cervical Cancers
Interventions
DRUG

Placebo

Participants will receive placebo (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).

DRUG

Misoprostol

Participants will receive 600 mcg misoprostol (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).

Trial Locations (1)

2034

RECRUITING

Cameroon Baptist Convention Health Core, EtougEbe Baptist Hospital Yaoundé, Yaoundé

All Listed Sponsors
collaborator

Cameroon Baptist Convention Health Core

UNKNOWN

lead

University of Alabama at Birmingham

OTHER